Abstract | INTRODUCTION: METHODS: Eligible patients had stage IIIB, IV, or recurrent NSCLC with progression on the oral EGFR TKIs gefitinib or erlotinib. Cetuximab was administered intravenously at 400 mg/m on day 1 and then 250 mg/m weekly until disease progression or unacceptable toxicity. The primary end point was response rate. RESULTS: Eighteen patients were enrolled. Patients were heavily pretreated with chemotherapy and TKIs (average number of treatments = 4.2). The response rate was 0/18 (0%), and 28% of patients had confirmed stable disease. Median progression-free survival was 1.8 months (95% confidence interval, 1.6-5.4 months), and median overall survival was 7.5 months (95% confidence interval, 2.2-19 months). Three patients harbored activating EGFR mutations, and one of them had stable disease for nearly 6 months on cetuximab. Common toxicities were mild and included fatigue, skin rash, and nausea/ vomiting. Two patients developed interstitial lung disease, life threatening in one case. CONCLUSIONS:
Cetuximab monotherapy administered after prior EGFR TKI treatment in patients with advanced NSCLC does not yield clinical responses.
|
Authors | Joel W Neal, Rebecca S Heist, Panos Fidias, Jennifer S Temel, Mark Huberman, J Paul Marcoux, Alona Muzikansky, Thomas J Lynch, Lecia V Sequist |
Journal | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
(J Thorac Oncol)
Vol. 5
Issue 11
Pg. 1855-8
(Nov 2010)
ISSN: 1556-1380 [Electronic] United States |
PMID | 20975380
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Protein Kinase Inhibitors
- EGFR protein, human
- ErbB Receptors
- Cetuximab
|
Topics |
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
(therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology)
- Cetuximab
- Drug Resistance, Neoplasm
(drug effects)
- ErbB Receptors
(antagonists & inhibitors, genetics)
- Female
- Humans
- Lung Neoplasms
(drug therapy, pathology)
- Male
- Middle Aged
- Mutation
(genetics)
- Neoplasm Recurrence, Local
(diagnosis, drug therapy)
- Neoplasm Staging
- Protein Kinase Inhibitors
(therapeutic use)
- Remission Induction
- Salvage Therapy
- Survival Rate
- Treatment Outcome
|